S100B Profiles and Cognitive Function at High Altitude
(2010) In High Altitude Medicine & Biology 11(1). p.31-38- Abstract
- Bjursten, Henrik, Per Ederoth, Engilbert Sigurdsson, Magnus Gottfredsson, Ingvar Syk, Orri Einarsson, and Tomas Gudbjartsson. S100B profiles and cognitive function at high altitude. High Alt. Med. Biol. 11:31-38, 2010.-Exposure to high altitude can lead to acute mountain sickness (AMS) and high altitude cerebral edema (HACE). In this study we investigated the effect of high altitude on neurocognitive function and S100B release. Increased S100B release has been hypothesized to signify a loss of integrity in the blood-brain barrier (BBB). Seven healthy volunteers trekked to Capanna Regina Margherita (4554 m above sea level) in the Monte Rosa massif. During ascent and descent, five test events were undertaken; participants underwent... (More)
- Bjursten, Henrik, Per Ederoth, Engilbert Sigurdsson, Magnus Gottfredsson, Ingvar Syk, Orri Einarsson, and Tomas Gudbjartsson. S100B profiles and cognitive function at high altitude. High Alt. Med. Biol. 11:31-38, 2010.-Exposure to high altitude can lead to acute mountain sickness (AMS) and high altitude cerebral edema (HACE). In this study we investigated the effect of high altitude on neurocognitive function and S100B release. Increased S100B release has been hypothesized to signify a loss of integrity in the blood-brain barrier (BBB). Seven healthy volunteers trekked to Capanna Regina Margherita (4554 m above sea level) in the Monte Rosa massif. During ascent and descent, five test events were undertaken; participants underwent neurocognitive testing, Lake Louise scoring (LLS), and blood sampling to measure levels of S100B. The blood tests revealed that S100B levels increased 42% to 122% from baseline, and mean LLS increased from 0.57 to 2.57. A significant correlation was observed between both S100B levels and LLS and S100B and some neurocognitive scores. The study indicates that S100B can be released by a mild hypoxia during AMS. Moreover, an observed correlation between S100B and a lower score on neurocognitive tests suggests that the pathogenetic mechanisms may be linked. The study indicates that a decline in cognitive function is associated with symptoms of AMS. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1587055
- author
- Bjursten, Henrik LU ; Ederoth, Per LU ; Sigurdsson, Engilbert ; Gottfredsson, Magnus ; Syk, Ingvar LU ; Einarsson, Orri and Gudbjartsson, Tomas
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- neurocognitive function, S100B, blood-brain barrier (BBB), high altitude cerebral edema (HACE), acute mountain sickness (AMS)
- in
- High Altitude Medicine & Biology
- volume
- 11
- issue
- 1
- pages
- 31 - 38
- publisher
- Mary Ann Liebert, Inc.
- external identifiers
-
- wos:000276172100005
- scopus:77954729568
- pmid:20367486
- ISSN
- 1527-0297
- DOI
- 10.1089/ham.2009.1041
- language
- English
- LU publication?
- yes
- id
- 35d307e9-15f9-43b3-b40e-ef120dfbb6b9 (old id 1587055)
- date added to LUP
- 2016-04-01 10:41:39
- date last changed
- 2022-02-25 04:49:54
@article{35d307e9-15f9-43b3-b40e-ef120dfbb6b9,
abstract = {{Bjursten, Henrik, Per Ederoth, Engilbert Sigurdsson, Magnus Gottfredsson, Ingvar Syk, Orri Einarsson, and Tomas Gudbjartsson. S100B profiles and cognitive function at high altitude. High Alt. Med. Biol. 11:31-38, 2010.-Exposure to high altitude can lead to acute mountain sickness (AMS) and high altitude cerebral edema (HACE). In this study we investigated the effect of high altitude on neurocognitive function and S100B release. Increased S100B release has been hypothesized to signify a loss of integrity in the blood-brain barrier (BBB). Seven healthy volunteers trekked to Capanna Regina Margherita (4554 m above sea level) in the Monte Rosa massif. During ascent and descent, five test events were undertaken; participants underwent neurocognitive testing, Lake Louise scoring (LLS), and blood sampling to measure levels of S100B. The blood tests revealed that S100B levels increased 42% to 122% from baseline, and mean LLS increased from 0.57 to 2.57. A significant correlation was observed between both S100B levels and LLS and S100B and some neurocognitive scores. The study indicates that S100B can be released by a mild hypoxia during AMS. Moreover, an observed correlation between S100B and a lower score on neurocognitive tests suggests that the pathogenetic mechanisms may be linked. The study indicates that a decline in cognitive function is associated with symptoms of AMS.}},
author = {{Bjursten, Henrik and Ederoth, Per and Sigurdsson, Engilbert and Gottfredsson, Magnus and Syk, Ingvar and Einarsson, Orri and Gudbjartsson, Tomas}},
issn = {{1527-0297}},
keywords = {{neurocognitive function; S100B; blood-brain barrier (BBB); high altitude cerebral edema (HACE); acute mountain sickness (AMS)}},
language = {{eng}},
number = {{1}},
pages = {{31--38}},
publisher = {{Mary Ann Liebert, Inc.}},
series = {{High Altitude Medicine & Biology}},
title = {{S100B Profiles and Cognitive Function at High Altitude}},
url = {{http://dx.doi.org/10.1089/ham.2009.1041}},
doi = {{10.1089/ham.2009.1041}},
volume = {{11}},
year = {{2010}},
}